Changes in surface antigen and e antigen in patients with chronic hepatitis B treated with PEG-IFN and entecavir and the predictive effect on the efficacy

Abstract

Objective To dynamically observe the changes of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen in the treatment of chronic hepatitis B patients treated with PEG-IFN and entecavir, analyze the predictive effect of the level changes on the therapeutic effect. Methods A total of 117 cases of chronic hepatitis B were treated with PEG-IFN or entecavir treatment, followed-up for 48 weeks, quantitatively examinated the each observation point of HBsAg, HBeA in patients; depending on the medication type of patients(PEG-IFN or entecavir) and HBeAg whether positive, the patients were divided into four different treatment groups, HBeAg positive PEG-IFN group (P+ group), HBeAg negative PEG-IFN group (P-group), HBeAg positive entecavir group (E+ group), HBeAg negative entecavir group (E-group); according to the immune response after 48 weeks, the patients were divided into complete response group and non-complete response group. The trend of HBsAg and HBeAg levels in different treatment group and response group were compared. Results The characteristics of the changes of HBsAg and HBeAg during the treatment process: ① The level of HBsAg and HBeAg decreased in the four treatment groups after treatment; ②Compared with group E+ , the difference of HBsAg and HBeAg between P+ group and E+ group was not significant compared with that of 0 week (P>0.05). Compared with group E-, the HBsAg level of each group was lower than that of group E- (P 0.05). Conclusions The level of HBsAg and HBeAg in patients with chronic hepatitis B treated with PEG-IFN and entecavir showed a downward trend in the treatment process; compared with HBsAg, HBeAg can better predict a complete response to 48 weeks; HBsAg and HBeAg for 12 and 24 weeks in patients with HBeAg positive chronic hepatitis B can predict 48 weeks’ complete response; the 12 week HBsAg in the PEG-IFN treatment group with chronic hepatitis B with negative HBeAg was of predictive value for the 48 week complete response. Key words: Chronic hepatitis B; Anti-virus; Hepatitis B surface antigens; Hepatitis B e Antigen; Effect prediction